CORRECTED-MARKET PULSE-Ariad Pharmaceuticals
(Corrects to say the European agency backed continued use of the drug, not that it recommended first approval)
Nov 22 (Reuters) -
** ARIAD PHARMACEUTICALS INC, Thursday close $2.79, up 25 pct premarket
The company said European regulators recommended the continued use of its leukemia drug, Iclusig, whose U.S. sale has been suspended due to safety concerns. (Compiled by Natalie Grover; Editing by Sriraj Kalluvila)
© Thomson Reuters 2017 All rights reserved.